Fibrosarcoma
Symptoms, Doctors, Treatments, Advances & More

Learn About Fibrosarcoma

What is the definition of Fibrosarcoma?
A fibroblastic sarcoma is a malignant tumor derived from fibrous connective tissue and characterized by immature proliferating fibroblasts or undifferentiated anaplastic spindle cells.
What are the alternative names for Fibrosarcoma?
  • Fibrosarcoma
Who are the top Fibrosarcoma Local Doctors?
Elite in Fibrosarcoma
Thoracic Surgery
Elite in Fibrosarcoma
Thoracic Surgery
Referral may be required

Baylor Scott & White Center For Thoracic Surgery - Dallas

3410 Worth St, Ste 760, 
Dallas, TX 
Languages Spoken:
English
Offers Telehealth

Dr. Schwartz is a thoracic surgeon with expertise in thoracic oncology, minimally invasive thoracic surgery, airway surgery, lung transplantation and extracorporeal membrane oxygenation. He completed a year of research focusing on thoracic oncology and endoscopic airway interventions. He has published many peer-reviewed publications and earned multiple clinical awards, including Chief Resident of the Year and the Charles McBurney Award. In addition, Dr. Schwartz serves in the following roles at Baylor University Medical Center: Chief, Department of Thoracic Surgery; Surgical Director, Lung Transplantation; Medical Director, Extracorporeal Membrane Oxygenation; and Surgical Director, Major Airway Disorders. He is married with four children and enjoys traveling, cooking, swimming and yoga. See Dr. Schwartz's Publications. Dr. Schwartz is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, Lung Transplant, and Gastrostomy. Dr. Schwartz is board certified in General Surgery- American Board Of Surgery/General Surgery, Thoracic And Cardiac Surgery- American Board Of Thoracic Surgery/Thoracic And Cardiac Surgery, General Surgery- American Board Of Surgery, and Thoracic And Cardiac Surgery- American Board Of Thoracic Surgery.

Elite in Fibrosarcoma
Surgical Oncology
Elite in Fibrosarcoma
Surgical Oncology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
Languages Spoken:
English

Christina Roland is a Surgical Oncologist practicing medicine in Cary, North Carolina. Dr. Roland is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. She is also highly rated in 24 other conditions, according to our data. Her clinical expertise encompasses Undifferentiated Pleomorphic Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Fibrosarcoma
Oncology | Hematology | Internal Medicine
Elite in Fibrosarcoma
Oncology | Hematology | Internal Medicine
Referral may be required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception E, 
Ann Arbor, MI 
Languages Spoken:
English
Offers Telehealth

Rashmi Chugh is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. She is also highly rated in 32 other conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma.

What are the latest Fibrosarcoma Clinical Trials?
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Summary: BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/meta...

Match to trials
Find the right clinical trials for you in under a minute
Get started
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center